Trial Profile
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs JZP 258 (Primary)
- Indications Cataplexy; Narcolepsy
- Focus Registrational; Therapeutic Use
- Sponsors Jazz Pharmaceuticals Inc
- 23 Oct 2023 Results of exploratory, post-hoc analysis presented in the Jazz Pharmaceuticals Media Release.
- 11 Sep 2023 According to a Jazz Pharmaceuticals plc media release, sub-group analysis data from this study was presented at the 36th annual Psych Congress, held September 6-10, 2023.
- 27 Apr 2023 Results(n=74) assessing long-term safety and tolerability of Low-Sodium Oxybate in Participants With Narcolepsy With Cataplexy presented at the 75th Annual Meeting of the American Academy of Neurology 2023